William M Mendenhall1, Primož Strojan2, Anne W M Lee3, Alessandra Rinaldo4, Avraham Eisbruch5, Wai Tong Ng6, Robert Smee7, Alfio Ferlito8. 1. Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA. 2. Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia. 3. Department of Clinical Oncology, University of Hong Kong Shenzhen Hospital, University of Hong Kong, Hong Kong, China. 4. University of Udine, School of Medicine, Udine, Italy. 5. Department of Radiation Oncology, University of Michigan Medicine, Ann Arbor, Michigan, USA. 6. Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 7. Department of Radiation Oncology, The Prince of Wales Cancer Centre, Sydney, New South Wales, Australia. 8. International Head and Neck Scientific Group, Padua, Italy.
Abstract
INTRODUCTION: Our purpose is to review the role radiotherapy (RT) in the treatment of glottic squamous cell carcinoma (SCC). METHODS: A concise review of the pertinent literature. RESULTS: RT cure rates are Tis- T1N0, 90% to 95%; T2N0, 70% to 80%; low-volume T3-T4a, 65% to 70%. Concomitant cisplatin is given for T3-T4a SCCs. Severe complications occur in 1% to 2% for Tis-T2N0 and 10% for T3-T4a SCCs. Patients with high-volume T3-T4 SCCs undergo total laryngectomy, neck dissection, and postoperative RT. Those with positive margins and/or extranodal extension receive concomitant cisplatin. The likelihood of local-regional control at 5 years is 85% to 90%. Severe complications occur in 5% to 10%. CONCLUSIONS: RT is a good treatment option for patients with Tis-T2N0 and low-volume T3-T4a glottic SCCs. Patients with higher volume T3-T4 cancers are best treated with surgery and postoperative RT.
INTRODUCTION: Our purpose is to review the role radiotherapy (RT) in the treatment of glottic squamous cell carcinoma (SCC). METHODS: A concise review of the pertinent literature. RESULTS: RT cure rates are Tis- T1N0, 90% to 95%; T2N0, 70% to 80%; low-volume T3-T4a, 65% to 70%. Concomitant cisplatin is given for T3-T4a SCCs. Severe complications occur in 1% to 2% for Tis-T2N0 and 10% for T3-T4a SCCs. Patients with high-volume T3-T4 SCCs undergo total laryngectomy, neck dissection, and postoperative RT. Those with positive margins and/or extranodal extension receive concomitant cisplatin. The likelihood of local-regional control at 5 years is 85% to 90%. Severe complications occur in 5% to 10%. CONCLUSIONS: RT is a good treatment option for patients with Tis-T2N0 and low-volume T3-T4a glottic SCCs. Patients with higher volume T3-T4 cancers are best treated with surgery and postoperative RT.